• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

    11/14/24 4:55:56 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DBVT alert in real time by email
    SC 13G/A 1 dbvt_sc13ga_2.htm SC 13G/A 1 ef20021615_sc13ga.htm SC 13G/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

    DBV TECHNOLOGIES S.A.
    (Name of Issuer)

    Ordinary shares, nominal value €0.10 per share
    (Title of Class of Securities)

    23306J200**
    (CUSIP Number)

    September 30, 2024
    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    **This is the CUSIP for the American Depositary Shares, each representing one-half of one Ordinary Share.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Continued on following pages
    Page 1 of 8 Pages



    CUSIP No. 23306J200
    Page 2 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
    BRAIDWELL LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)☐
    (b)☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    10,162,9611
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    10,162,9611
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    10,162,9611
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.99%2
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IA, PN

    1 Consists of 3,300,000 Shares (as defined herein), Shares issuable upon the exercise of 6,010,000 immediately exercisable pre-funded warrants (“Warrants”) subject to the Beneficial Ownership Limitation (defined below), and 1,630,542 American Depositary Shares (“ADS”), all of which are directly owned by Braidwell Partners Master Fund LP. Each ADS represents the right to receive one-half of one Share. The Warrants are subject to a blocker which prevents the holder from exercising the Warrants to the extent that, upon such exercise, the holder would beneficially own in excess of 9.99% of the Shares outstanding as a result of the exercise (the “Beneficial Ownership Limitation”).
    2 Based on 96,498,927 Shares outstanding as of July 30, 2024, as reported in the Issuer’s quarterly report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission (the “SEC”) on July 30, 2024, plus the total number of Shares that the Reporting Persons have the right to acquire upon exercise of Warrants, subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.


    CUSIP No. 23306J200
    Page 3 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
    BRAIDWELL MANAGEMENT LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)☐
    (b)☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    10,162,9611
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    10,162,9611
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    10,162,9611
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.99%2
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    HC, OO


    CUSIP No. 23306J200
    Page 4 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
    ALEXANDER T. KARNAL
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)☐
    (b)☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Connecticut
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    10,162,9611
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    10,162,9611
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    10,162,9611
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.99%2
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IN, HC


    CUSIP No. 23306J200
    Page 5 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
    BRIAN J. KREITER
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)☐
    (b)☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    10,162,9611
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    10,162,9611
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    10,162,9611
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    9.99%2
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    HC, OO


    CUSIP No. 23306J200
    Page 6 of 8 Pages
    Item 1(a).
    Name of Issuer:

    DBV Technologies S.A.

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    107 Av. de la République
    92320 Châtillon France

    Item 2(a).
    Name of Person Filing

    This filing is being jointly filed by the Reporting Persons.

    Item 2(b).
    Address of Principal Business Office or, if None, Residence:

    The business address of each Reporting Person is:
    2200 Atlantic St
    4th Floor
    Stamford, CT 06902

    Item 2(c).
    Citizenship:

    Braidwell LP is a limited partnership organized under the laws of the State of Delaware. Braidwell Management LLC is a limited liability company organized under the laws of the State of Delaware. Alexander Karnal and Brian Kreiter are both citizens of the United States of America.

    Item 2(d).
    Title of Class of Securities:

    Ordinary shares, nominal value €0.10 per share (the “Shares”)

    Item 2(e).
    CUSIP Number:

    23306J200 (This is the CUSIP for the American Depositary Shares, each representing one-half of one Ordinary Share)

    Item 3.
    If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

    (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E)
    (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G)


    CUSIP No. 23306J200
    Page 7 of 8 Pages
    Item 4.
    Ownership:

    Item 4(a)
    Amount Beneficially Owned:

    Items 5-9 of each cover page are incorporated by reference. As of September 30, 2024, each Reporting Person may be deemed to be the beneficial owner of 10,162,961 Shares, which amount consists of 3,300,000 Shares, Shares issuable upon the exercise of 60,010,000 Warrants subject to the Beneficial Ownership Limitation, and 1,630,542 ADS, all of which are directly owned by Braidwell Partners Master Fund LP.

    Item 4(b)
    Percent of Class:

    As of September 30, 2024, each Reporting Person may be deemed to beneficially own 9.99% of the Shares, which is calculated based on 96,498,927 Shares outstanding as of July 30, 2024, as reported in the Issuer’s quarterly report on Form 10-Q for the quarterly period ended June 30, 2024 filed with the SEC on July 30, 2024, plus the total number of Shares that the Reporting Persons have the right to acquire upon exercise of Warrants, subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.

    Item 4(c)
    Number of Shares as to which such person has:

    (i) Sole power to vote or direct the vote: 0
    (ii) Shared power to vote or direct the vote: 10,162,9611
    (iii) Sole power to dispose or direct the disposition of: 0
    (iv) Shared power to dispose or direct the disposition of: 10,162,9611

    Item 5.
    Ownership of Five Percent or Less of a Class:

    n/a

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person:

    n/a

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

    The information in Item 4 is incorporated herein.

    Item 8.
    Identification and Classification of Members of the Group:

    n/a

    Item 9.
    Notice of Dissolution of Group:

    n/a

    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    CUSIP No. 23306J200
    Page 8 of 8 Pages
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Nobvember 14, 2024


    BRAIDWELL MANAGEMENT LLC
    AS GENERAL PARTNER OF BRAIDWELL LP





    BY:
    /S/ MANISH K. MITAL


    NAME: MANISH K. MITAL


    TITLE: AUTHORIZED SIGNATORY




    BRAIDWELL MANAGEMENT LLC



    BY:
    /S/ MANISH K. MITAL


    NAME: MANISH K. MITAL


    TITLE: AUTHORIZED SIGNATORY






    ALEXANDER T. KARNAL

    /s/ ALEXANDER T. KARNAL






    BRIAN J. KREITER


    /s/ BRIAN J. KREITER



    Get the next $DBVT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DBVT

    DatePrice TargetRatingAnalyst
    5/29/2025$7.25Sell
    Goldman
    1/4/2023Hold → Buy
    Societe Generale
    12/16/2022Neutral → Sell
    Goldman
    5/10/2022$6.00 → $1.50Buy → Neutral
    Goldman
    12/21/2021$8.00 → $5.00Market Outperform
    JMP Securities
    12/21/2021$14.00 → $10.00Buy
    HC Wainwright & Co.
    9/14/2021Hold → Buy
    Societe Generale
    More analyst ratings

    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Mohideen Pharis sold $1,030 worth of Ordinary Shares (464 units at $2.22), decreasing direct ownership by 0.42% to 109,649 units (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    7/31/25 4:15:16 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Mohideen Pharis sold $730 worth of Ordinary Shares (397 units at $1.84), decreasing direct ownership by 0.36% to 110,113 units (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    5/27/25 4:10:06 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Epic Bpifrance claimed ownership of 10,898,595 units of Ordinary Shares (SEC Form 3)

    3 - DBV Technologies S.A. (0001613780) (Issuer)

    5/20/25 4:01:38 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

    Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, at 2:00 p.m. ET in Boston, Massachusetts. A live webcast of the fireside chat be accessed here and will also be available on the Events section of the Company's Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event. About DBV

    11/4/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

    Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su

    11/3/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025

    Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345   Date   Total number of shares Total number of voting rights 10/31/2025   179,827,919     Total gross of voting rights: 179,827,919     Total net* of voting rights: 179,741,847   * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

    11/3/25 4:25:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Tasse Daniel bought $14,188 worth of Ordinary Shares (17,094 units at $0.83) (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    3/11/24 4:15:38 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ndu Adora bought $1,624 worth of Ordinary Shares (1,825 units at $0.89) (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    2/8/24 5:02:03 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on DBV Technologies with a new price target

    Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25

    5/29/25 8:17:33 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies upgraded by Societe Generale

    Societe Generale upgraded DBV Technologies from Hold to Buy

    1/4/23 7:23:06 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies downgraded by Goldman

    Goldman downgraded DBV Technologies from Neutral to Sell

    12/16/22 7:41:19 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by DBV Technologies S.A.

    SCHEDULE 13D/A - DBV Technologies S.A. (0001613780) (Subject)

    11/4/25 4:14:45 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies S.A. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - DBV Technologies S.A. (0001613780) (Filer)

    10/30/25 4:49:57 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies S.A. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - DBV Technologies S.A. (0001613780) (Filer)

    10/28/25 5:40:13 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Leadership Updates

    Live Leadership Updates

    View All

    DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

    Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr. Trapp will report directly to Daniel Tasse, Chief Executive Officer, as a member of the executive team and will lead all aspects of global commercial strategy and execution for the Viaskin® Peanut patch. DBV expects to submit a Biologics License Application (BLA) submission for children 4-7 years-old living with peanut allergy in the first half of 2026, followed by an anticipated BLA su

    11/3/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

    Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the "Board"), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company's shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company's Board comprises ten directors. "We are pleased

    10/30/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Resignation of Board Member

    Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the "Board"), effective immediately. "On behalf of the Board, DBV's management team and shareholders, I thank Daniel for his commitment to the Company," said Michel de Rosen, Chairman of the Board. "Since joining the Board in 2015, Daniel's experience, insights and expertise have been invaluable to the Board and its Compensation Committee. We wish him continued success in his future endeavors." "It has been a

    9/18/25 4:30:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Financials

    Live finance-specific insights

    View All

    DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

    Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc

    6/25/25 4:15:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

    Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE    DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FD

    1/8/25 4:05:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

    Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-oldCompany to host investor webcast today at 5:00pm ET DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, tod

    12/11/24 4:05:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    11/14/24 4:55:56 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    2/14/24 8:56:45 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

    SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

    2/14/24 4:06:12 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care